Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 18, pp. 2004-2012
Open Access | Times Cited: 1133

Showing 1-25 of 1133 citing articles:

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo, Sabine Karam, Nupur N. Uppal, et al.
American Journal of Nephrology (2017) Vol. 45, Iss. 2, pp. 160-169
Open Access | Times Cited: 15005
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 17, pp. 1627-1639
Open Access | Times Cited: 8719
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 2, pp. 123-135
Open Access | Times Cited: 7940
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith, et al.
Science (2017) Vol. 357, Iss. 6349, pp. 409-413
Open Access | Times Cited: 5686
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 17, pp. 1714-1768
Open Access | Times Cited: 3127
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, et al.
The Lancet (2016) Vol. 389, Iss. 10066, pp. 299-311
Open Access | Times Cited: 2855
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
John B.A.G. Haanen, Franck Carbonnel, Caroline Robert, et al.
Annals of Oncology (2017) Vol. 28, pp. iv119-iv142
Open Access | Times Cited: 2138
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2122
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
American Journal of Clinical Oncology (2015) Vol. 39, Iss. 1, pp. 98-106
Open Access | Times Cited: 1941
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Jean‐Marie Michot, Camille Bigenwald, Stéphane Champiat, et al.
European Journal of Cancer (2016) Vol. 54, pp. 139-148
Closed Access | Times Cited: 1919
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 21, pp. 1976-1986
Open Access | Times Cited: 1797
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Jarushka Naidoo, David B. Page, Bob T. Li, et al.
Annals of Oncology (2015) Vol. 26, Iss. 12, pp. 2375-2391
Open Access | Times Cited: 1358
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 11, pp. 1497-1508
Open Access | Times Cited: 1309
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, et al.
Journal of the National Comprehensive Cancer Network (2017) Vol. 15, Iss. 4, pp. 504-535
Open Access | Times Cited: 1213
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 18, pp. 4585-4593
Open Access | Times Cited: 1062
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian, Aaron Lisberg, Krikor Bornazyan, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 7, pp. 895-903
Open Access | Times Cited: 977
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Mizuki Nishino, Nikhil H. Ramaiya, Hiroto Hatabu, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 11, pp. 655-668
Open Access | Times Cited: 904
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, et al.
The Lancet Oncology (2016) Vol. 18, Iss. 1, pp. 31-41
Open Access | Times Cited: 885
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
John Kwon, Samuel F. Bakhoum
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 26-39
Open Access | Times Cited: 854
Management of toxicities of immune checkpoint inhibitors
Lavinia Spain, Stefan Diem, James Larkin
Cancer Treatment Reviews (2016) Vol. 44, pp. 51-60
Closed Access | Times Cited: 796
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Valsamo Anagnostou, Kellie N. Smith, Patrick M. Forde, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 264-276
Open Access | Times Cited: 793
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller, Young‐Chul Kim, Heather Cronin, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 4, pp. 886-894
Open Access | Times Cited: 789
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon, Matthew D. Hellmann, Naiyer A. Rizvi, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 28, pp. 2518-2527
Open Access | Times Cited: 774
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Éric Bouffet, Valérie Larouche, Brittany Campbell, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 19, pp. 2206-2211
Closed Access | Times Cited: 761
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
Claire F. Friedman, Tracy Proverbs‐Singh, Michael A. Postow
JAMA Oncology (2016) Vol. 2, Iss. 10, pp. 1346-1346
Closed Access | Times Cited: 728
Page 1 - Next Page

Scroll to top